Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Report on panitumumab for first line treatment of RAS wild type mCRC from ASCO 2022

Reporting from ASCO 2022 Annual Meeting in Chicago, Chiara Cremolini puts into context presented research on panitumumab first-line therapy in RAS wild-type metastatic Colorectal Cancer. She details the results from the PARADIGM trial testing chemotherapy plus panitumumab vs chemotherapy plus bevacizumab, evidence from the TRIPLETE trial on the benefit of chemotherapy intensification with panitumumab, and findings from the IMPROVE study testing intermittent vs continuous panitumumab plus chemotherapy in this setting.

This video was supported with an unrestricted grant from Novartis.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.